U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07500090) titled 'A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)' on March 21.
Brief Summary: This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in treating idiopathic hypersomnia (IH) symptoms, including excessive daytime sleepiness (EDS), sleep inertia, and fatigue in adult participants (ages >=18 years) with idiopathic hypersomnia (IH).
The primary objective of this study is to evaluate the efficacy of HBS-301 compared with placebo in treating IH symptoms.
Secondary objectives include evaluating ...